Table 2.
The association of the prevalence of kidney stones and testosterone evaluated by logistic regression analysis in subgroups stratified by age.
| Unadjusted, OR (95% CI) | P-value | Adjusted b, OR (95% CI) | P-value | |
|---|---|---|---|---|
| All, Testosteronea | ||||
| Q1 (≤287.40) | 2.04 (1.607–2.585) | <0.001 | 1.375 (1.061–1.781) | 0.016 |
| Q2 (287.41–386.00) | 1.691 (1.324–2.158) | <0.001 | 1.348 (1.041–1.739) | 0.021 |
| Q3 (386.10–510.47) | 1.578 (1.233–2.020) | <0.001 | 1.472 (1.144–1.895) | 0.003 |
| Q4 (>510.48) | reference | reference | ||
| P for trend | <0.001 | 0.117 | ||
| Age (20–40), Testosteronea | ||||
| Q1 (≤313.69) | 1.531 (0.920–2.549) | 0.101 | – | – |
| Q2 (313.7–418.0) | 1.038 (0.599–1.801) | 0.893 | – | – |
| Q3 (418.1–542.0) | 1.282 (0.757–2.171) | 0.355 | – | – |
| Q4 (>542.01) | reference | – | – | |
| P for trend | 0.178 | |||
| Age (41–60), Testosteronea | ||||
| Q1 (≤280.31) | 2.391 (1.565–3.654) | <0.001 | 1.904 (1.212–2.991) | 0.005 |
| Q2 (280.31–370.00) | 1.785 (1.149–2.775) | 0.010 | 1.599 (1.021–2.503) | 0.040 |
| Q3 (370.10–492.22) | 1.827 (1.177–2.836) | 0.007 | 1.734 (1.113–2.700) | 0.015 |
| Q4 (>492.23) | reference | reference | ||
| P for trend | <0.001 | 0.001 | ||
| Age (61–80), Testosteronea | ||||
| Q1 (≤268.0) | 1.613 (1.134–2.296) | 0.008 | 1.169 (0.789–1.731) | 0.436 |
| Q2 (268.1–360.9) | 1.776 (1.252–2.520) | 0.001 | 1.471 (1.016–2.129) | 0.041 |
| Q3 (361.0–492.0) | 1.582 (1.110–2.254) | 0.011 | 1.466 (1.020–2.106) | 0.039 |
| Q4 (>492.1) | reference | reference | ||
| P for trend | 0.008 | 0.966 |
CI, confidence interval; HR, hazard ratio.
a
Presented in quartiles (ng/dl).
b
Adjusted for age, race, BMI, hypertension, diabetes, gout, coronary heart, disease, arthritis, angina, heart attack, stroke, smoking, serum total cholesterol, triglycerides, calcium, and uric acid.